Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Sanofi seeks U.S. and E.U. approval for sotagliflozin in type 1 diabetes

March 27, 2018

EMA grants PRIME designation for lumasiran in primary hyperoxaluria type 1

March 27, 2018

Amag submits NDA for bremelanotide for hypoactive sexual desire disorder

March 27, 2018

Male contraceptive 11beta-MNTDC reduces testosterone in healthy male volunteers

March 27, 2018

New indication, new formulation of Signifor LAR approved in Japan

March 26, 2018

Novel thrombopoietin receptor agonists synthesized at Sichuan Kelun-Biotech Biopharmaceutical

March 26, 2018

EMA recommends including new indication in Repatha label

March 26, 2018

Cellivery investigates leptin-targeting antiobesity therapy

March 26, 2018

vTv Therapeutics completes phase Ib of Simplici-T1 trial of TTP-399 in type 1 diabetes

March 23, 2018

Ozempic approved in Japan

March 23, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...